Literature DB >> 31250081

[Rivaroxaban versus warfarin in high-risk patients with antiphospholipid syndrome].

Denitsa Hadjiski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31250081     DOI： 10.1007/s00393-019-0659-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  3 in total

1.  Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome.

Authors:  Entela Nuri; Mara Taraborelli; Laura Andreoli; Marta Tonello; Maria Gerosa; Antonia Calligaro; Lorenza Maria Argolini; Rajesh Kumar; Vittorio Pengo; Pier Luigi Meroni; Amelia Ruffatti; Angela Tincani
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.

Authors:  V Pengo; A Banzato; E Bison; G Zoppellaro; S Padayattil Jose; G Denas
Journal:  Lupus       Date:  2015-10-13       Impact factor: 2.911

3.  Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Authors:  Vittorio Pengo; Gentian Denas; Giacomo Zoppellaro; Seena Padayattil Jose; Ariela Hoxha; Amelia Ruffatti; Laura Andreoli; Angela Tincani; Caterina Cenci; Domenico Prisco; Tiziana Fierro; Paolo Gresele; Arturo Cafolla; Valeria De Micheli; Angelo Ghirarduzzi; Alberto Tosetto; Anna Falanga; Ida Martinelli; Sophie Testa; Doris Barcellona; Maria Gerosa; Alessandra Banzato
Journal:  Blood       Date:  2018-07-12       Impact factor: 22.113
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.